Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.60
-0.0300-1.84%
Pre-market: 1.740.1378+8.61%05:09 EDT
Volume:33.86K
Turnover:54.45K
Market Cap:8.98M
PE:-0.45
High:1.64
Open:1.62
Low:1.56
Close:1.63
52wk High:6.04
52wk Low:1.47
Shares:5.61M
Float Shares:5.32M
Volume Ratio:0.66
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:4.64
PE(LYR):-0.23

Loading ...

Imunon - Reports Enrollment Rate Exceeding Forecast in Ovation 3 Trial

THOMSON REUTERS
·
Jul 30

Imunon Reports Strong Enrollment Momentum in Phase 3 Ovation 3 Trial of Imnn-001 in Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 30

Imunon - Projects Enrollment Completion in Q2 2029 for Ovation 3 Trial

THOMSON REUTERS
·
Jul 30

Imunon Announces Press Release Available

Reuters
·
Jul 23

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

GlobeNewswire
·
Jul 23

Imunon General Counsel Susan Eylward Disposes of 2,150 Common Shares Worth $3,830.44

Reuters
·
Jul 22

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response

MT Newswires Live
·
Jul 21

Imunon announces new preliminary data from IMNN-001 trial

TIPRANKS
·
Jul 21

Imunon - Imnn-001 Under Evaluation in Phase 3 Ovation 3 Trial for Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon Reports Positive Phase 2 Mrd Clinical Data for Imnn-001, Demonstrating the Successful Overcoming of Historical Il-12 Safety Barriers in Frontline Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon - no Cytokine Release Syndrome or Serious Immune-related Adverse Events Observed with Imnn-001

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Demonstrates Lower Mrd Rate, Higher Ctdna Clearance, and Higher Ned Rate vs Control

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Shows Highly Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jul 21

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

GlobeNewswire
·
Jul 21

Imunon Files Form 3 for CFO Joshua Blacher

Reuters
·
Jul 08

Imunon General Counsel Susan Eylward Disposes of 920 Common Shares Worth $1,729.6

Reuters
·
Jul 08

Imunon interim CFO Jeffrey Church to retire, Josh Blacher to succeed

TIPRANKS
·
Jul 01

Imunon - Jeffrey Church to Retire as Interim CFO Effective July 1, 2026 - SEC Filing

THOMSON REUTERS
·
Jul 01

Imunon Names Josh Blacher Interim CFO Effective July 1

Reuters
·
Jul 01

Imunon General Counsel Susan Eylward Sells 11,800 Common Shares for $20,674.8

Reuters
·
Jun 30